Orchestration of immune checkpoints in tumor immune contexture and their prognostic significance in esophageal squamous cell carcinoma

References

• RustgiAKEl-SeragHBEsophageal carcinomaN Engl J Med2014371262499250925539106
   PubMed Web of Science ®Google Scholar
• HanahanDWeinbergRAThe hallmarks of cancerCell20001001577010647931
   PubMed Web of Science ®Google Scholar
• GiraldoNABechtERemarkRDamotteDSautès-FridmanCFridmanWHThe immune contexture of primary and metastatic human tumoursCurr Opin Immunol20142781524487185
   PubMed Web of Science ®Google Scholar
• ZitvogelLGalluzziLKeppOSmythMJKroemerGType I interferons in anticancer immunityNat Rev Immunol201515740541426027717
   PubMed Web of Science ®Google Scholar
• FridmanWHPagèsFSautès-FridmanCGalonJThe immune contexture in human tumours: impact on clinical outcomeNat Rev Cancer201212429830622419253
   PubMed Web of Science ®Google Scholar
• DongHChenLB7-H1 pathway and its role in the evasion of tumor immunityJ Mol Med (Berl)200381528128712721664
   PubMed Web of Science ®Google Scholar
• DongHZhuGTamadaKChenLB7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretionNat Med19995121365136910581077
   PubMed Web of Science ®Google Scholar
• LatchmanYWoodCRChernovaTPD-L2 is a second ligand for PD-1 and inhibits T cell activationNat Immunol20012326126811224527
   PubMed Web of Science ®Google Scholar
• KeirMEButteMJFreemanGJSharpeAHPD-1 and its ligands in tolerance and immunityAnnu Rev Immunol20082667770418173375
   PubMed Web of Science ®Google Scholar
• FengZXiang-LeiLHai-TaoWProgrammed cell death 1 expression in esophageal squamous cell carcinoma and association with clinical characteristicsIndian J Cancer201552Suppl 3E17617827453418
   PubMedGoogle Scholar
• ChenLDengHLuMB7-H1 expression associates with tumor invasion and predicts patient’s survival in human esophageal cancerInt J Clin Exp Pathol2014796015602325337246
   PubMed Web of Science ®Google Scholar
• OhigashiYShoMYamadaYClinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancerClin Cancer Res20051182947295315837746
   PubMed Web of Science ®Google Scholar
• BrahmerJReckampKLBaasPNivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung CancerN Engl J Med2015373212313526028407
   PubMed Web of Science ®Google Scholar
• SongYLiLOuYIdentification of genomic alterations in oesophageal squamous cell cancerNature20145097498919524670651
   PubMed Web of Science ®Google Scholar
• KojimaTDoiTImmunotherapy for Esophageal Squamous Cell CarcinomaCurr Oncol Rep20171953328361224
   PubMed Web of Science ®Google Scholar
• ChauvinJMPaglianoOFourcadeJTIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patientsJ Clin Invest201512552046205825866972
   PubMed Web of Science ®Google Scholar
• JohnstonRJComps-AgrarLHackneyJThe immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector functionCancer Cell201426692393725465800
   PubMed Web of Science ®Google Scholar
• HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
   PubMed Web of Science ®Google Scholar
• MotzerRJEscudierBMcDermottDFNivolumab versus Everolimus in Advanced Renal-Cell CarcinomaN Engl J Med2015373191803181326406148
   PubMed Web of Science ®Google Scholar
• Abdel-LatifMMDugganSReynoldsJVKelleherDInflammation and esophageal carcinogenesisCurr Opin Pharmacol20099439640419596608
   PubMed Web of Science ®Google Scholar
• DeansDAWigmoreSJGilmourHPaterson-BrownSRossJAFearonKCElevated tumour interleukin-1beta is associated with systemic inflammation: A marker of reduced survival in gastro-oesophageal cancerBr J Cancer200695111568157517088911
   PubMed Web of Science ®Google Scholar
• DoyleSLDonohoeCLFinnSPIGF-1 and its receptor in esophageal cancer: association with adenocarcinoma and visceral obesityAm J Gastroenterol2012107219620422146489
   PubMed Web of Science ®Google Scholar
• HongSLeeHJKimSJHahmKBConnection between inflammation and carcinogenesis in gastrointestinal tract: focus on TGF-beta signalingWorld J Gastroenterol201016172080209320440848
   PubMed Web of Science ®Google Scholar
• JenkinsGJMikhailJAlhamdaniAImmunohistochemical study of nuclear factor-kappaB activity and interleukin-8 abundance in oesophageal adenocarcinoma; a useful strategy for monitoring these biomarkersJ Clin Pathol200760111232123717220207
   PubMed Web of Science ®Google Scholar
• LiuJLiFPingYLocal production of the chemokines CCL5 and CXCL10 attracts CD8+ T lymphocytes into esophageal squamous cell carcinomaOncotarget2015628249782498926317795
   PubMedGoogle Scholar
• O’SullivanKEPhelanJJO’HanlonCLysaghtJO’SullivanJNReynoldsJVThe role of inflammation in cancer of the esophagusExpert Rev Gastroenterol Hepatol20148774976024857183
   PubMed Web of Science ®Google Scholar
• ShankaranVIkedaHBruceATIFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicityNature200141068321107111111323675
   PubMed Web of Science ®Google Scholar
• PagèsFKirilovskyAMlecnikBIn situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancerJ Clin Oncol200927355944595119858404
   PubMed Web of Science ®Google Scholar
• ZhangLConejo-GarciaJRKatsarosDIntratumoral T cells, recurrence, and survival in epithelial ovarian cancerN Engl J Med2003348320321312529460
   PubMed Web of Science ®Google Scholar
• GiraldoNABechtEPagèsFOrchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell CancerClin Cancer Res201521133031304025688160
   PubMed Web of Science ®Google Scholar
• MurisJJMeijerCJCillessenSAPrognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomasLeukemia200418358959614712286
   PubMed Web of Science ®Google Scholar
• ScottDWChanFCHongFGene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphomaJ Clin Oncol201331669270023182984
   PubMed Web of Science ®Google Scholar
• AbikoKMatsumuraNHamanishiJIFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancerBr J Cancer201511291501150925867264
   PubMed Web of Science ®Google Scholar
• BellucciRMartinABommaritoDInterferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expressionOncoimmunology201546e100882426155422
   PubMed Web of Science ®Google Scholar
• BrahmerJRTykodiSSChowLQSafety and activity of anti-PD-L1 antibody in patients with advanced cancerN Engl J Med2012366262455246522658128
   PubMed Web of Science ®Google Scholar
• TopalianSLHodiFSBrahmerJRSafety, activity, and immune correlates of anti-PD-1 antibody in cancerN Engl J Med2012366262443245422658127
   PubMed Web of Science ®Google Scholar
• ZhangYWangLLiYProtein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinomaOnco Targets Ther2014756757324748806
   PubMed Web of Science ®Google Scholar
• HamanishiJMandaiMIwasakiMProgrammed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancerProc Natl Acad Sci U S A200710493360336517360651
   PubMed Web of Science ®Google Scholar
• ShiMRoemerMGChapuyBExpression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gainAm J Surg Pathol201438121715172325025450
   PubMed Web of Science ®Google Scholar